In a study published on August 31, 2023, in the Journal of the American Medical Association, psilocybin showed promise as a treatment for major depressive disorder (MDD). JAMA Associate Editor Dr. Donald C. Goff, speaks with publication author Dr. Charles L. Raison, from the Usona Institute, about the study, as well as Dr. Rachel Yehuda from Mount Sinai School of Medicine, who wrote an accompanying editorial about the potential benefits of psychedelic therapies. Pacific Neuroscience Institute's director of Treatment & Research In Psychedelics Center, Dr. Keith Heinzerling and PNI director Dr. Daniel Kelly were a co-investigators in this study.

In a study published on August 31, 2023, in the Journal of the American Medical Association, psilocybin showed promise as a treatment for major depressive disorder (MDD). JAMA Associate Editor Dr. Donald C. Goff, speaks with publication author Dr. Charles L. Raison, from the Usona Institute, about the study, as well as Dr. Rachel Yehuda from Mount Sinai School of Medicine, who wrote an accompanying editorial about the potential benefits of psychedelic therapies. Pacific Neuroscience Institute's director of Treatment & Research In Psychedelics Center, Dr. Keith Heinzerling and PNI director Dr. Daniel Kelly were a co-investigators in this study.

In a study published on August 31, 2023, in the Journal of the American Medical Association, psilocybin showed promise as a treatment for major depressive disorder (MDD). JAMA Associate Editor Dr. Donald C. Goff, speaks with publication author Dr. Charles L. Raison, from the Usona Institute, about the study, as well as Dr. Rachel Yehuda from Mount Sinai School of Medicine, who wrote an accompanying editorial about the potential benefits of psychedelic therapies. Pacific Neuroscience Institute's director of Treatment &amp; Research In Psychedelics Center, Dr. Keith Heinzerling and PNI director Dr. Daniel Kelly were a co-investigators in this study.

46. Psilocybin for Major Depressive Disorder | Guest Podcast

The Think Neuro podcast from Pacific Neuroscience Institute takes you into the clinic, operating room and laboratory with doctors and surgeons who are tackling the most challenging brain diseases and disorders. You’ll go deep into the brain and beyond, exploring the neurological processes and structures that control our health, hormones, behaviors, movements, moods, and emotions. You’ll learn about new therapies that are giving hope for sufferers of the most challenging diseases, and you’ll hear about some habits you can develop to keep your brain in good working order for years to come. We’ll show you why patients from around the world are coming to Pacific Neuroscience Institute for novel treatments that are in many instances, available at few other institutions.

pacificneuro.org  |  (310) 582-7640

Think Neuro’s host is Anthony Effinger, an award-winning journalist who is fascinated with neuroscience and the workings of the brain. Anthony spent 24 years at Bloomberg News, where he covered money and finance, with deep forays into science and health. In 2006, the Association of Health Care Journalists awarded him first prize for Playing the Odds, an in-depth piece on the changing strategies used to treat prostate cancer. These days, he is a staff writer at Willamette Week, a Pulitzer Prize-winning newspaper in Portland, Oregon, where he lives with his wife and two children. He won the 2022 award for health care journalism from the Association of Alternative Newsmedia for his piece on the disproven Covid remedy ivermectin and the anti-vaxx Portland biologist who was its biggest booster.

Science

Medicine

Health & Fitness

Mental Health

Life Sciences

The Think Neuro podcast from Pacific Neuroscience Institute takes you into the clinic, operating room and laboratory with doctors and surgeons who are tackling the most challenging brain diseases and disorders. You’ll go deep into the brain and beyond, exploring the neurological processes and structures that control our health, hormones, behaviors, movements, moods, and emotions. You’ll learn about new therapies that are giving hope for sufferers of the most challenging diseases, and you’ll hear about some habits you can develop to keep your brain in good working order for years to come. We’ll show you why patients from around the world are coming to Pacific Neuroscience Institute for novel treatments that are in many instances, available at few other institutions. pacificneuro.org | (310) 582-7640 Think Neuro’s host is Anthony Effinger, an award-winning journalist who is fascinated with neuroscience and the workings of the brain. Anthony spent 24 years at Bloomberg News, where he covered money and finance, with deep forays into science and health. In 2006, the Association of Health Care Journalists awarded him first prize for Playing the Odds, an in-depth piece on the changing strategies used to treat prostate cancer. These days, he is a staff writer at Willamette Week, a Pulitzer Prize-winning newspaper in Portland, Oregon, where he lives with his wife and two children. He won the 2022 award for health care journalism from the Association of Alternative Newsmedia for his piece on the disproven Covid remedy ivermectin and the anti-vaxx Portland biologist who was its biggest booster.

Share 46. Psilocybin for Major Depressive Disorder | Guest Podcast

Sign up to save your podcasts

46. Psilocybin for Major Depressive Disorder | Guest Podcast

46. Psilocybin for Major Depressive Disorder | Guest Podcast

More shows like Think Neuro

NPR News Now

On Being with Krista Tippett

Neurology® Podcast

The Joe Rogan Experience

The Daily

Up First from NPR

Core IM | Internal Medicine Podcast

Behind the Bastards

Dhru Purohit Show

Neurology Today in 5

The Parkinson's Podcast

The Clinical Problem Solvers

Neurology Minute

Neuro-Oncology: The Podcast

The Energy of Money Podcast